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ABSTRACT:
Trastuzumab has been shown to improve the survival outcomes of HER2 positive 
breast cancer patients. However, a significant proportion of HER2-positive patients 
are either inherently resistant or develop resistance to trastuzumab. We assessed the 
effects of neratinib, an irreversible panHER inhibitor, in a panel of 36 breast cancer 
cell lines. We further assessed its effects with or without trastuzumab in several 
sensitive and resistant breast cancer cells as well as a BT474 xenograft model. We 
confirmed that neratinib was significantly more active in HER2-amplified than HER2 
non-amplified cell lines. Neratinib decreased the activation of the 4 HER receptors 
and inhibited downstream pathways. However, HER3 and Akt were reactivated at 
24 hours, which was prevented by the combination of trastuzumab and neratinib. 
Neratinib also decreased pHER2 and pHER3 in acquired trastuzumab resistant cells. 
Neratinib in combination with trastuzumab had a greater growth inhibitory effect 
than either drug alone in 4 HER2 positive cell lines. Furthermore, trastuzumab in 
combination with neratinib was growth inhibitory in SKBR3 and BT474 cells which had 
acquired resistance to trastuzumab as well as in a BT474 xenograft model. Innately 
trastuzumab resistant cell lines showed sensitivity to neratinib, but the combination 
did not enhance response compared to neratinib alone. Levels of HER2 and phospho-
HER2 showed a direct correlation with sensitivity to neratinib. Our data indicate 
that neratinib is an effective anti-HER2 therapy and counteracted both innate and 
acquired trastuzumab resistance in HER2 positive breast cancer. Our results suggest 
that combined treatment with trastuzumab and neratinib is likely to be more effective 
than either treatment alone for both trastuzumab-sensitive breast cancer as well as 
HER2-positive tumors with acquired resistance to trastuzumab.  
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INTRODUCTION
HER2 is a member of the human epidermal growth 
factor receptor (HER) family which also includes EGFR 
(HER1), HER3 and HER4 [1]. The HER proteins are 
receptor tyrosine kinases which consist of an extracellular 
domain, an α-helical transmembrane region and an 
intracellular tyrosine kinase domain [2]. The crystal 
structure of HER2 shows that the extracellular domain 
is constitutively in an ‘open’ conformation, ready for 
dimerization [3]. Although HER2 has no known ligand, 
it is the preferred heterodimerization partner of the other 
HER receptors and is involved in the lateral transmission 
of signals between other HER family receptors [4]. The 
HER2/HER3 dimer is considered to be the most potent 
with regards to strength of interaction, ligand-induced 
tyrosine phosphorylation and downstream signaling [5, 
6]. HER2 signaling promotes cell proliferation via the 
RAS-ERK pathway and inhibits cell death via the PI3K-
Akt-mTOR pathway [7]. Over-expression of HER2 occurs 
in approximately 20% of breast cancers and is associated 
with a poor prognosis [8, 9]. 
Trastuzumab is a humanized monoclonal antibody 
which binds to extracellular domain IV of HER2. It 
has been shown to increase survival in HER2 positive 
metastatic and early breast cancer patients, especially 
when given in combination with chemotherapy [10, 11]. 
Trastuzumab is thought to exert its anti-tumor activity 
partly by accelerating the internalization and degradation 
of HER2 and thus blocking downstream signaling. In 
addition, it may also act by mediating antibody-dependent-
cellular cytotoxicity [12]. However, many patients do not 
respond to trastuzumab and the majority who initially 
respond, progress within a year of initiating therapy [13]. 
Understanding the mechanisms responsible for resistance 
to trastuzumab is therefore crucial for the development of 
new therapeutic strategies and improving patient outcome. 
Based on preclinical studies, mechanisms of 
primary and acquired resistance to trastuzumab include 
(i) activation of PI3K/Akt signaling due to PTEN loss or 
PI3KCA mutations [14, 15], (ii) the presence of p95HER2, 
a truncated form of HER2 [16]; (iii) interaction of HER2 
with other receptors such as IGF-IR and c-Met [17, 18] 
and (iv) activation of HER receptors by an Akt negative 
feedback loop [19]. Other proposed mechanisms include 
the constitutive activation of the autophagy-related gene 
12 (ATG12) [20], the presence of trastuzumab-refractory 
breast cancer stem cells (CSCs) [21], and the steric 
hindrance caused by association of HER2 with other cell 
surface signaling proteins, i.e. integrins  β1, CD44, MUC1 
and MUC4 [22].
In an attempt to circumvent resistance to 
trastuzumab, anti-HER2 tyrosine kinase inhibitors (TKIs) 
were introduced. The first TKI to show activity in HER2 
positive breast cancer patients was the dual EGFR/HER2 
reversible TKI, lapatinib [23]. In patients who were 
resistant to trastuzumab, the combination of lapatinib 
with capecitabine increased median time to progression 
compared to capecitabine alone [23]. As a result, lapatinib 
with capecitabine is currently licensed for use in patients 
who have previously failed trastuzumab. Clinical trials 
have shown that the addition of trastuzumab and lapatinib 
to chemotherapy achieved a higher pathological complete 
response than either trastuzumab or lapatinib alone [24, 
25]. 
To further enhance HER2 inhibition, irreversible 
TKIs, such as neratinib, afatinib and dacomitinib have 
been developed. Neratinib, is an irreversible inhibitor of 
EGFR, HER2 and HER4 tyrosine kinase activity [26] 
shown to have promising preclinical activity against 
HER2-overexpressing cell lines [27]. Indeed, it is 
currently undergoing several phase 3 clinical trials [28, 
29]. Since we have previously shown that trastuzumab-
induced activation of all HER receptors may contribute 
to trastuzumab resistance [19], we assessed the effects 
of neratinib, to determine if it can improve response and 
overcome resistance to trastuzumab, in sensitive and 
resistant HER2 amplified breast cancer cells. 
RESULTS
Neratinib sensitivity in a panel of breast cancer 
cell lines
We determined sensitivity to neratinib in a panel 
of 36 breast cancer cell lines, including HER2 positive, 
luminal and basal-like cell lines (Figure 1A left panel, 
Supplementary Table 1). The HER2 positive cell lines 
(n=12) were significantly more sensitive to neratinib, than 
either the triple negative (n=15, p=0.0002) or luminal 
cell lines (n=9, p=0.0055) (Figure 1A, right panel). 
One luminal cell line however, MDA-MB-175, showed 
sensitivity to neratinib (IC50 value < 0.001 µM), while one 
of the HER2 positive cell lines, UACC-732, was relatively 
insensitive to neratinib (IC50 value = 0.65 µM). The IC50 
values for neratinib were lower than those previously 
published for lapatinib in the panel of HER2 positive 
cell lines [30]. The results were also confirmed by direct 
comparison of the two drugs in SKBR3 and BT474 cells, 
and both cell lines showed greater sensitivity to neratinib 
than lapatinib (data not shown).
Neratinib decreases pHER2 in a dose-dependent 
manner in HER2 amplified breast cancer cells
As the HER2 positive cell lines were significantly 
more sensitive to neratinib, we investigated the effect 
of neratinib on HER2 signalling in two HER2 positive 
breast cell lines. One hour of neratinib (2 nM) treatment 
did not decrease pHER2 levels despite inhibition of pAkt 
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and pERK (Figure 1B). However, pHER2 was inhibited 
after 24 hours (Figure 1B). A dose dependent inhibition 
of pHER2 was observed with increasing concentrations 
of neratinib in both cell lines (Figure 1B). Although 
total HER2 levels were not altered by treatment with 
neratinib for 1 hour, by 24 hours HER2 level was reduced 
in response to 50 nM neratinib in SKBR3 and was 
undetectable in BT474 cells. 
Reactivation of pERK was observed after 24 
hours of neratinib treatment in SKBR3 cells, although 
the highest concentration of neratinib (50 nM) inhibited 
this reactivation (Figure 1B). The reactivation of pERK 
was not seen in BT474 cells, which are more sensitive 
than SKBR3 cells (Figure 1B). The results suggest 
that neratinib effectively inhibits HER2 activation and 
downstream signaling in HER2 positive breast cell lines.
Combined treatment with neratinib and 
trastuzumab has an additive effect
To assess the effect of trastuzumab with neratinib, 
SKBR3 and BT474 cells were treated with 40 µg/
ml trastuzumab, 2 nM neratinib or the combination for 
six days. The combination treatment was significantly 
more effective in reducing cell numbers compared to 
trastuzumab alone (p< 0.001) or neratinib alone (p< 
0.05) in both cells lines (Figure 2A). To understand the 
enhanced response to the combination, a time-course 
experiment was performed to assess the effect of the 
combination on HER receptor activation and downstream 
signaling. Figure 2B shows the results after three days 
of treatment  in the SKBR3 cells (data for BT474 cells 
are not shown as there were insufficient cells left after 
three days of the combination treatment). Trastuzumab 
Figure 1: Neratinib is most effective in HER2 positive breast cell lines and reduces HER2 phosphorylation. A) Neratinib 
IC50 values (μM) and breast cancer cell type. Cell lines are color coded by subtype: white bars - HER2 amplified; black bars – triple 
negative; stripes – luminal. Differences between the cell line subtypes were analysed by Mann-Whitney U test. * p <0.05. B) BT474 (right) 
and SKBR3 (left) cell were treated for 1 hour or 1 day with increasing concentrations of neratinib. After lysis, protein levels were assessed 
using western blotting techniques.
Oncotarget 2013; 4:1595www.impactjournals.com/oncotarget
decreased pHER3 and pAkt only minimally after 1 hour 
and did not decrease pEGFR, pHER2, pHER4 or pERK 
at the timepoints tested (Figure 2B and Supplementary 
Figure 1). In contrast, 1-hour neratinib treatment 
inhibited phosphorylation of EGFR, HER2, HER3 and 
HER4 as well as pAkt and pERK levels (Figure 2B and 
Supplementary Figure 1). However, reactivation of HER3 
and Akt phosphorylation was observed after 24 hours 
(Figure 2B and Supplementary Figure 1). The combination 
of trastuzumab and neratinib prevented reactivation of 
pHER3 and pAkt and downregulated EGFR and HER2 at 
3 days (Figure 2B and Supplementary Figure 1).  
Neratinib is effective in acquired trastuzumab 
resistant HER2 amplified cells 
We tested the effect of neratinib on acquired 
trastuzumab resistant BT474 (BT474R) and SKBR3 
(SKBR3R) cells. With increasing doses, neratinib inhibited 
pHER2 and pHER3 as well as downstream pathways 
in both cell lines at 1 hour and 1 day (Figure 3A). We 
also assessed the effect of trastuzumab withdrawal and/
or neratinib treatment in resistant cells. In the BT474R 
and SKBR3R cells, withdrawal of trastuzumab increased 
the cell count significantly, compared to trastuzumab 
replacement or continuous treatment with trastuzumab 
Figure 2: Combination of neratinib and trastuzumab has an additive effect and prevents re-activation of pHER3 
and pAkt. A) BT474 (left) and SKBR3 (right) cells are treated for 5 days with either 40 µg/ml trastuzumab or 2 nM neratinib or their 
combination (n=3, both technical and biological replicates are represented in the figures). DMSO is used as a vehicle control for neratinib. 
Cells were trypsinized and counted using a cell counter. The differences in means of the cell count between the groups were analysed by 
Anova with Bonferroni’s multiple comparison test and statistically significant changes were represented by asterisks (*, P ≤ 0.05; ***, P ≤ 
0.001). B) SKBR3 cells were treated with 2 nM neratinb, 40 µg/ml trastuzumab or their combination for the indicated times before the cells 
were lysed and analysed by western blot. 
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(Figure 3B). Neratinib monotherapy decreased cell 
numbers to a greater extent than trastuzumab replacement, 
in both resistant cell lines (Figure 3B). Furthermore, the 
combination of trastuzumab and neratinib had a greater 
growth inhibitory effect than either drug alone, with or 
without trastuzumab withdrawal in SKBR3R (Figure 3B).
Combined treatment with neratinib and 
trastuzumab in a panel of HER2 amplified cell 
lines 
Based on the additive interaction between neratinib 
and trastuzumab observed in the SKBR3 and BT474 
cell lines, we extended the analysis of the combination 
treatment to 7 additional HER2 amplified breast cancer 
cell lines, including cell line models of innate trastuzumab 
resistance.  In the MDA-MB-361 and EFM-192-A cell 
lines, which are moderately sensitive to trastuzumab, 
the combination of neratinib and trastuzumab showed 
greater inhibition of growth than either of the drugs alone 
(Figure 4A). However in the trastuzumab-resistant cell 
lines (JIMT1, MDA-MB-453, HCC1419, HCC1954, 
UACC732) the combination treatment showed no 
enhancement compared to neratinib alone (Figure 4B and 
Supplementary Figure 2). 
Figure 3: Trastuzumab resistant cells are sensitive to neratinib treatment. A) Trastuzumab resistant SKBR3 (SKBR3R, left) 
or BT474R (right) cells were treated for 1 hour or 1 day with increasing doses of neratinib. The cells were continuously kept in media 
with 40 µg/ml trastuzumab. Cells were lysed and protein levels analysed by western blot. B) SKBR3R (left) and BT474R (right) cells 
were treated for 5 days with 2 nM of neratinib, 40ug/ml trastuzumab or their combination. Cells were trypsinized and counted using a cell 
counter. Cells were either seeded out with 40 µg/ml trastuzumab in the media or plated out overnight without trastuzumab for 16 hours in 
the media before treatment was commended the next day. The differences in means of the cell count between the groups were analysed by 
Anova with Bonferroni’s multiple comparison test and statistically significant changes were represented by asterisks (*, P ≤ 0.05; **, P ≤ 
0.01; ***, P ≤ 0.001).
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Response to neratinib correlates with HER2 and 
pHER2 in HER2 amplified breast cancer cell lines
In order to identify potential predictive biomarkers 
for neratinib sensitivity in HER2 positive breast cancer, 
we correlated the neratinib IC50 values with a panel of 
potential biomarkers previously measured by O’Brien 
et al [30] to determine their relationship with response/
resistance to lapatinib and/or trastuzumab. In the panel 
of 11 HER2 positive breast cancer cell lines, higher 
baseline levels of both HER2 and phosphorylated 
HER2 significantly correlated with response to neratinib 
(p=0.038 and 0.042 respectively) (Figure 5A). Neratinib 
sensitivity was not significantly associated with p95-
HER2, EGFR, HER3, Akt, ERK, PTEN, PI3K mutation 
status or ER status (Supplementary Table 2). 
Correlation between the effect of neratinib on cell 
signaling and biomarkers 
In order to examine potential pharmacodynamic 
biomarkers of response to neratinib, we tested the 
effects of neratinib (200 nM) on HER2 and downstream 
signalling in a panel of HER2 amplified cell lines, with 
varying sensitivity to neratinib (Figure 5B). In all cell lines 
tested, neratinib significantly reduced phosphorylation of 
HER2, although the level of reduction did not correlate 
with sensitivity to neratinib (Figure 5C). Neratinib 
inhibited phosphorylation of Akt and ERK to a greater 
extent in cell lines which are more sensitive to neratinib 
(pAkt: p=0.026; pERK: p=0.012). 
Figure 4: Combined neratinib and trastuzumab treatment in cell line models with varying trastuzumab sensitivity 
and resistance. Sensitivity to trastuzumab and neratinib in A) two trastuzumab moderately sensitive and B) two innately trastuzumab 
resistant HER2 positive breast cancer cell lines. Cells were treated with neratinib alone, trastuzumab alone or the combination at a fixed 
ratio for 5 days.
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Combined treatment with trastuzumab and 
neratinib is additive in a BT474 xenograft model 
We further examined the effect of neratinib and/or 
trastuzumab in a BT474 xenograft model and showed that 
the combination treatment resulted in the greatest tumour 
inhibition (Figure 6A), correlated with the final tumor 
volume in vivo among the four groups (vehicle control 
vs combination group, p< 0.05; all other comparisons, 
p > 0.05) (Supplementary Figure 3A left panel). The 
combination treatment also resulted in the smallest tumor 
weight ex-vivo (vehicle control vs combination group, p< 
0.05; all other comparisons, p > 0.05) (Supplementary 
Figure 3A right panel) and with higher percentage of 
connective tissue ex-vivo compared to vehicle control (p< 
0.001) or neratinib alone (p< 0.01) (Figure 6B). 
Immunohistochemical (IHC) staining in the 
xenograft tumors showed no statistically difference in 
the levels of membrane HER2 and pHER2 between any 
of the groups although the trastuzumab and neratinib 
combination treatment showed the lowest IRS scoring 
for pHER2 staining (Figure 6C and 6D). In contrast to 
HER2, staining for pHER3 was weak but the lowest IRS 
scoring was seen in the combination arm (Supplementary 
Figure 3B). Consistent with the cell line data, neratinib 
and trastuzumab inhibited pAkt to a greater extent than 
trastuzumab monotherapy but not neratinib monotherapy 
(Figure 6E and Supplementary Figure 3C). Neratinib 
treatment showed little effect on ERK phosphorylation 
whereas trastuzumab alone and the combination treatment 
decreased pERK staining in the xenograft tumors 
(Figure 6F and Supplementary Figure 3C). However, the 
differences in pHER3, pAkt and pERK IHC staining were 
not statistically significant.
Figure 5: Levels of HER2 and pHER2 predict response to neratinib. A) Scatter plots showing the relationship between the 
levels of both HER2 protein and pHER2 (determined by western blotting) and neratinib sensitivity (IC50). B) The effects of neratinib on 
expression and phosphorylation of HER2, Akt and ERK in HER2 positive breast cancer cell lines. C) Scatter plots showing the relationship 
between the neratinib (200 nM) induced decrease in phosphorylation of HER2, Akt and ERK and neratinib sensitivity (IC50) in 9 HER2 
positive breast cancer cell lines.
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DISCUSSION
Our results showed that the combination of 
trastuzumab and neratinib treatment was significantly 
more potent at reducing cell viability than trastuzumab 
alone in both sensitive and acquired resistant HER2 
over-expressing SKBR3 and BT474 breast cancer cells. 
In the trastuzumab-naïve SKBR3 and BT474 cells, acute 
neratinib treatment inhibited phosphorylation of EGFR, 
HER2, HER3 and HER4 as well as downstream pathways 
Figure 6: Combination of trastuzumab and neratinib was additive in tumor growth inhibition in BT474 xenograft 
model. A) Left, Mice bearing BT474 xenograft tumors were treated with either control (vehicle), neratinib, trastuzumab or their combination 
for 16 days. During this time, tumor size was measured in each mouse and the tumor volume calculated. B) At the end of the experiment 
from A, tumor samples were collected and embedded in paraffin. The slides were cut and analysed for the percentage of connective tissue 
per section. The differences in means of the percentage of connective tissue between the groups were analyzed by Anova with Bonferroni’s 
multiple comparison test and statistically significant changes were indicated in the figure. C-F), Sections were cut from paraffin-embedded 
xenograft samples and stained for HER2, phosphorylated HER2 (pHER2), phosphorylated Akt (pAkt) and phosphorylated ERK (pERK). 
Sections were then scored for the intensity and percentage of staining. The IRS scoring from each condition was shown in the figures.
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ERK and Akt, reflecting its immediate inhibitory effect on 
the tyrosine kinase activity of all the HER receptors. In 
contrast, trastuzumab did not decrease phosphorylation 
of EGFR, HER2, HER4 and ERK, reflecting the different 
mechanisms of action of the drugs. The xenograft 
experiment also showed that the combination treatment 
lead to the greatest decrease in pHER2 with decreased 
activation of pAkt and pERK, correlating with increased 
efficacy compared to the single agents, in xenograft 
models. Although trastuzumab has been previously 
shown to downregulate HER2 [12, 19, 31], this effect 
was not seen with either trastuzumab, neratinib or the 
combination treatment in our xenograft study. This 
may be because there was a significant heterogeneity in 
HER2 staining between xenograft tumor areas and the 
dose of trastuzumab used in this study was lower than in 
previously reported xenograft experiments [31], which 
may affect the amount of HER2 downregulation and 
assessment [32].
Clinically, the withdrawal of trastuzumab treatment 
in patients who are no longer responding is controversial 
[33], partially due to the cost of continuing trastuzumab 
treatment [34]. Our data revealed that the withdrawal 
of trastuzumab from the trastuzumab-resistant cell lines 
resulted in a significantly increased cell count compared 
to continuation of trastuzumab treatment. Furthermore, 
the combination of trastuzumab and neratinib was 
significantly more effective than neratinib alone even in 
the presence of trastuzumab resistance. This is supported 
by recent data which showed that lapatinib in combination 
with trastuzumab significantly improved overall survival 
and progression-free survival compared to lapatinib alone 
despite disease progression on prior trastuzumab-based 
therapy [35, 36]. 
Neratinib has shown promising activity in several 
clinical trials, particularly in HER2 positive breast 
cancer patients [29, 37]. Neratinib and trastuzumab in 
combination with paclitaxel chemotherapy showed clinical 
benefit in patients who had been heavily pre-treated with 
anti-HER2 agents and chemotherapy, with a mean of 4 
prior regimens [38]. A phase II multi-centre randomized 
study of neratinib in combination with weekly paclitaxel 
with or without trastuzumab followed by doxorubicin 
and cyclophosphamide (AC) as neoadjuvant therapy 
for women with HER2-positive locally advanced breast 
cancer (NSABP FB-7) is currently ongoing. As well as 
neratinib, other irreversible TKIs including dacomitinib 
(PF-00299804) and afatinib (BIBW2992) are also 
being tested in clinical trials. Afatinib monotherapy was 
shown to have promising clinical activity in extensively 
pretreated HER2-positive breast cancer patients who had 
progressed following trastuzumab treatment [39].
It has been previously shown that EGFR and HER2 
inhibitors failed to suppress HER3 phosphorylation due 
to ligand-dependent activation of HER3 via ADAM17 
through an Akt feedback loop [19, 40, 41]. This could 
be an important drug resistance mechanism for EGFR 
and HER2 inhibitors. We showed that although neratinib 
effectively inhibited phosphorylation of all HER receptors 
for up to 24 hours, reactivation of HER3 and Akt occurred 
within 3 days. However, the combination of trastuzumab 
and neratinib significantly delayed reactivation of HER3 
and Akt compared to neratinib alone. In contrast a recent 
study showed that dual inhibition with trastuzumab 
and lapatinib or trastuzumab and pertuzumab does not 
completely eliminate HER3 function [42]. It would be 
interesting to determine if the reactivation of HER3 
observed with neratinib is also induced by ADAM17 
mediated heregulin release [19]. This possibility might be 
investigated using an ADAM17 inhibitor or a monoclonal 
antibody to HER3.
Although neratinib is a panHER inhibitor, we 
showed that it is selectively active in HER2 amplified 
compared to non-amplified breast cancer cell lines. 
However, some of the HER2 amplified cells listed in 
Supplementary Table1, including MDA-MB-361 and 
MDA-MB-453, have been classified as IHC 2+ or HER2 
negative [43-46], as they express slightly lower levels 
of HER2 protein, at an expression level that is nearer 
to the original FDA definition of HER2 positivity [47]. 
Since HER2 testing results may be variable according to 
the methods or assays of testing [48], it is not surprising 
that some of these cells have been classified differently. 
Nevertheless, some of the moderate HER2 expressing 
breast cancer cells including MDA-MB-453 and MDA-
MB-361 show greater sensitivity to neratinib than 
trastuzumab. In NSABP B-41, lapatinib in combination 
with chemotherapy induced a greater pathological 
complete response than that of trastuzumab in combination 
with chemotherapy in breast cancer patients with IHC 2+ 
although the number of patients in each arm was small 
[49]. Thus it may be important to assess the effect of 
neratinib in patients whose tumors express lower levels of 
HER2 protein (IHC 2+). 
Despite the frequent overexpression of EGFR in 
triple negative breast tumors and cell lines, they were 
less sensitive to neratinib than HER2 amplified cells. 
The luminal cell line, MDA-MB-175, which showed 
significant sensitivity to neratinib has previously been 
shown to be dependent on heregulin-mediated activation 
of HER2/HER3 signaling and are also more sensitive to 
pertuzumab treatment than trastuzumab [50]. In addition, 
neratinib but not lapatinib, has been shown to be active 
against HER2 somatic mutations present in about 1-3% of 
HER2 negative breast cancer patients [51]. This suggests 
that there may be both overlapping and non-overlapping 
mechanisms of resistance to different HER2 inhibitors. 
There is a need to further understand the biomarkers that 
can predict response to neratinib in different breast cancer 
subtypes. 
The levels of total HER2 protein and phosphorylated 
HER2 correlated with response to neratinib in the panel of 
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HER2 overexpressing cell lines, similar to lapatinib [30]. 
HER2 protein and mRNA levels have also been shown 
to predict response to dacomitinib [52]. The reduction in 
pAkt and pERK in response to neratinib treatment was 
also correlated with sensitivity to neratinib. Other potential 
biomarkers which may be predictive of response to 
neratinib, and other HER2 targeted therapies, include the 
dimerization states of the HER receptors [53], and levels 
of protein tyrosine phosphatases, such as PTPN9 which 
has been shown to regulate EGFR and HER2 activation 
[54, 55].
Like lapatinib [30], neratinib can overcome 
trastuzumab resistance in cell line models of acquired 
trastuzumab resistance and can enhance response to 
trastuzumab in trastuzumab sensitive cell lines. However, 
neratinib also shows activity in some cell lines which are 
innately resistant to lapatinib which suggests that neratinib 
may have clinical benefit in patients who do not respond 
to trastuzumab and/or lapatinib. The challenge will be 
to identify predictive markers to select those patients 
with HER2 positive breast cancer who may benefit from 
neratinib treatment but not from trastuzumab or lapatinib. 
The results of this study provide a rational for clinical 
trials of neratinib in combination with trastuzumab and 
of neratinib alone (with chemotherapy) in patients whose 
disease has progressed on trastuzumab and/or lapatinib 
treatment.
MATERIALS AND METHODS
Cell lines and generation of trastuzumab resistant 
cell lines
SKBR3 and BT474 were obtained from CRUK 
London Research Institute Cell Services, and were 
cultured in RPMI and DMEM respectively; both were 
supplemented with 10% FBS, penicillin-streptomycin. 
Trastuzumab-resistant BT474 and SKBR3 cell lines were 
generated as previously described [19]. In addition to 
SKBR3 and BT474, the following panel of breast cancer 
cell lines was used in this study:  EFM192A, HCC1419, 
MDA-MB-361, MDA-MB-453, SUM190, SUM225, 
UACC732, UACC812, UACC893, CAMA1, EFM19, 
KPL1, MCF7, MDA-MB-134, MDA-MB-175, MDA-
MB-415, T47D, ZR751, HCC1569, HCC1954, BT20, 
BT549, CAL51, HCC38, HCC70, HCC1143, HCC1187, 
HCC1395, HCC1806, HCC1937, JIMT1, MDA-MB157, 
MDA-MB-231, MDA-MB-468, MDA-MB-435, MDA-
MB-436. All cell lines used were obtained from the 
American Type Culture Collection (Rockville, MD, USA) 
unless otherwise stated. EFM192A, KPL1, EFM19 and 
CAL51 were supplied by the German Tissue Repository 
DSMZ (Braunschweig, Germany). SUM190 and SUM225 
were obtained from the University of Michigan (Ann 
Arbor, MI, USA).  MDA-MB-134, MDA-MB-415, MDA-
MB-436, MDA-MB-157, UACC893 and UACC812 were 
cultured in L15 medium supplemented with 10 % heat-
inactivated fetal bovine serum (FBS), 2 mM glutamine 
and 1 % penicillin G-streptomycin-fungizone solution 
(PSF) (Irvine Scientific, Santa Ana, CA, USA). DMEM 
(Cellgro, Manassas, VA, USA) supplemented with 10 % 
heat-inactivated FBS and PSF (Irvine Scientific, Santa 
Ana, CA, USA) was used to culture CAL51 and KPL1. 
SUM190 and SUM225 were maintained in HAM’s F12 
supplemented with 5 % heat inactivated FBS, PSF, 5 mg/
ml insulin and 1 mg/ml hydrocortisone. All other cell lines 
were maintained in RPMI 1640 (Cellgro) supplemented 
with 10 % FBS (heat inactivated), 2 mM glutamine and 1 
% PSF (Irvine Scientific, Santa Ana, CA, USA). All cell 
lines were grown in a humidified incubator at 37 ˚C with 5 
% CO2 apart from MDA-MB-134, MDA-MB-157, MDA-
MB-175, MDA-MB-361, MDA-MB-415, MDA-MB-436, 
UACC812 and UACC893 which were grown at 37 ˚C in 
the absence of CO2. 
Stock solutions of lapatinib (10 mM) (Sequoia 
Research Products) and neratinib (10 mM) (supplied by 
Pfizer) were prepared in dimethyl sulfoxide (DMSO). 
Trastuzumab was purchased from St Vincent’s University 
Hospital and Oxford University Hospitals NHS Trust.
Proliferation assays
Proliferation was assessed using cell counting and acid 
phosphatase assays. 
For cell counting experiments, cells were seeded in 
duplicate at 2 – 3 x 104 cells per well, depending on the 
cell line, in 24 well plates.  The cells were treated for 5 
days unless otherwise stated. On the concluding day of 
the experiments, the cells were washed with phosphate 
buffered saline (PBS) before trypsinization and counted 
using ISOTON solution on the Coulter Z2 particle counter 
(Beckham Coulter, Inc). Growth inhibition relative to 
control treated cells was determined. The log of drug 
concentration was then plotted against the log growth 
inhibition and IC50 values were calculated using linear 
regression analysis as previously described [30].
For the acid phosphatase assay, 5 x 104 cells/well 
for MDA-MB-361 cells, and 3 x 104 cells/well for the 
other cell lines were seeded in triplicate 96-well plates. 
Following overnight incubation at 37°C, drugs were added 
at the appropriate concentrations and incubated for 5 days 
at 37°C. Cells were washed once with PBS and acid 
phosphatase substrate (7.25 mM p-nitrophenyl-phosphate 
(Sigma) in sodium acetate buffer) was added to each 
well and incubated at 37 ºC for 1 hour. The reaction was 
stopped by adding 50 µl 1 M NaOH and absorbance was 
read at 405 nm with 620 nm as the reference wavelength.
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Xenograft experiment
The flank of BALC/nu/nu mice was injected with 
107 BT474 cells in Matrigel and left to grow (under the 
project license PPL 30/2771). Mice were provided with 
5 µg/ml oestradiol in the drinking water for the duration 
of the experiment. When tumors reached an average 
size of 125 mm3, the mice were divided into 4 groups, 
keeping average tumor size similar between groups. The 
control group of 4 mice was treated with vehicle (0.5% 
methocellulose - 0.4% polysorbate-80 (Tween 80)) by 
gavage daily and sterile PBS intraperitoneally (IP) twice 
weekly. The treatment groups consisted of 5 mice, treated 
with: (i) vehicle containing neratinib 10 mg/kg by gavage 
daily and IP PBS twice a week; (ii) trastuzumab 10 mg/
kg (twice weekly IP) and vehicle by gavage daily; (iii) 
trastuzumab 10 mg/kg by IP twice a week with neratinib 
(10 mg/kg) by gavage daily. The treatment continued 
for 17 days (5 trastuzumab treatments) and the mice 
were sacrificed 3 hours after the last neratinib treatment. 
Tumours were weighed and collected in 4% formalin to 
fix over night at 4 °C. The samples were then embedded 
in paraffin for immunohistochemical analysis.
Western Blotting
Neratinib dose escalation studies in naïve and acquired 
resistant SKBR3 and BT474 cells
SKBR3 and BT474 cells were seeded and left to 
adhere overnight. Cells were treated as indicated before 
they were placed on ice and washed with PBS. Lysis 
buffer (10 mM EDTA, 20 mM Tris pH 7.5, 150 mM 
NaCl, 10 mM Na2P2O7 and 100 mM NaF with 1% Triton 
X and 1:100 protease inhibitor cocktail) was added to the 
cells and the cells scraped off the plates. Samples were 
centrifuged at 4°C to remove the insoluble cell pellets. 
Bradford Protein Assay was then performed to determine 
protein concentration. Equal amounts of protein sample 
were prepared in 4X SDS with 10% beta-mercaptoethanol, 
boiled for 10 minutes at 95°C. Samples were then loaded 
into a NuPage 4-12% gel and ran at 100V for 15 minutes 
then 130V until completion. The proteins were semi-dry 
transferred to a PVDF membrane for two hours at 12V. 
The membrane was blocked in 3% BSA in PBS-Tween 
(0.2%) for a minimum of one hour. The membrane was 
then incubated with primary antibody in 3% BSA in PBS-
Tween overnight at 4°C. All antibodies were purchased 
from Cell Signalling Technologies. The membrane was 
then washed four times with 1% milk in PBS-Tween 
(0.2%) at room temperature and incubated with secondary 
antibody in 5% milk PBS-Tween (0.2%) for one hour 
before washing four times in 1% milk PBS-Tween. Bands 
were then visualized and the blot developed using an 
enhanced chemiluminescent system (ECL, GE Heathcare). 
Bands were quantified using ImageJ software.
Pharmacodynamic biomarkers of neratinib response 
in a panel of cell lines
After neratinib treatment for 24h, cells were washed 
with PBS and lysed in RIPA buffer (Sigma) containing 
protease inhibitors, 1 mM phenylmethylsulfonyl fluoride 
(PMSF) and 1 mM sodium orthovanadate. After 20 
min incubation on ice, lysate was passed through a 
21-gauge needle and centrifuged at 10,000 g for 5 min 
at 4ºC. Protein quantification was carried out using the 
bicinchoninic acid assay (Pierce).
Forty µg of protein were solubilized in sample 
buffer (250 mM Tris–HCl; 10% sodium dodecyl 
sulphate (SDS); 5% beta-mercaptoethanol; 30% 
glycerol; 0.02% bromophenol blue), heated to 95 ºC for 
5 min and separated using 7.5% polyacrylamide gels 
(Lonza). Proteins were transferred to Hybond enhanced 
chemiluminescence nitrocellulose membrane (Amersham, 
Biosciences, Buckinghamshire, UK). The membrane 
was blocked with 5% milk in PBS–0.1% Tween at room 
temperature for 1h. After overnight incubation at 4ºC 
with primary antibody (anti-HER2, Calbiochem, all 
other antibodies from Cell Signaling Technology) in 5% 
blocking solution milk in PBS–0.1% Tween, three washes 
with PBS–0.1% Tween were carried out, followed by 
incubation at room temperature with secondary antibody 
in 5% blocking solution milk in PBS–0.1% Tween for 1 
hour. Following three washes with PBS–0.1% Tween and 
one PBS wash, protein bands were detected using Luminol 
(Santa Cruz Biotechnology Inc., Santa Cruz, CA).
Immunohistochemisty and immunoreactive (IRS) 
scoring 
Formalin-fixed BT474 xenograft samples were 
embedded in paraffin and 4 µm thick sections were cut 
for immunohistochemical staining. The sections were 
dewaxed and rehydrated prior to antigen retrieval using 
Tris/EDTA at pH9 for HER2 and phosho-HER2, or citrate 
buffer at pH6 for the other antibodies. Sections were 
blocked using horse serum (Vector laboratories) overnight 
at 4oC. The following day, sections were incubated with 
primary antibodies for 2 hours at room temperature, 
followed by 3 washes with PBS. The sections were then 
incubated with a horseradish peroxidise-coupled anti-
rabbit secondary antibody (Vector laboratories) for 30 
minutes at room temperature. Visualization of staining was 
performed using a diaminobenzidine (DAB) peroxidase 
substrate (Vector Laboratories). Counterstaining was 
performed using Haemocytoxin prior to the mounting 
using aqueous-based mounting media (Aquatex). Levels 
of staining were scored blindly. The scoring criteria is 
composite score based on staining intensity (SI) and 
percentage of positive cells (PP) using the formula IRS 
= SI × PP. The staining intensity (SI) was determined as 
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0 = negative; 1 = weak; 2 = moderate; and 3 = strong 
and the percentage of positive cells (PP) was defined as 
0, <1%; 1, 1%–10%; 2, 11%–50%; 3, 51%–80%; and 4, 
>80% positive cells.
Statistical analysis
Mann-Whitney U test was used to investigate the 
association between response to neratinib and breast 
cancer cell line subtype. The differences in the means 
between different conditions or groups (n>2) were 
analysed by Anova with Bonferroni’s multiple comparison 
test and p < 0.05 was taken to be statistically significant. 
Relationships between neratinib response and HER2, 
pHER2, p95, EGFR, HER3, Akt, ERK, PTEN, PI3K and 
ER (from O’Brien et al [30]) were examined using the 
Spearman’s Rank correlation and Mann-Whitney U test on 
StatView for Windows (version 5.0.1) (SAS Institute, Inc).
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